This marked the first FDA-approved oral GLP-1 medication specifically indicated for weight loss
Direct hepatic lipid oxidation is a mechanism unique to the retatrutide triple-agonist profile
April 24, 2026 Status Conference on Tuesday Attorneys in the federal GLP-1 vision loss MDL will appear before Judge Karen Spencer Marston on Tuesday for a status conference
[42] Tirzepatide has been reported to increase levels of adiponectin, an adipokine involved in the regulation of both glucose and lipid metabolism, with a maximum increase of 26% from baseline after 26 weeks, at the 10 mg dosage
The final pretreatment reading is presented at the zero-time point
BPC-157 Known for its potential to support tendon, ligament, muscle, and gastrointestinal healing